Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire

INTRODUCTION: Dysgeusia may occur during conventional or target-therapies and affect patients adherence-to-treatment. Therefore, it should be monitored to improve clinical outcome. To date, available questionnaires on dysgeusia relate to traditional antineoplastics and do not apply to target-therapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Camela, Elisa, Villani, Alessia, Ocampo Garza, Sonia Sofia, Costa, Claudia, Fabbrocini, Gabriella, Megna, Matteo, Potestio, Luca, Ruggiero, Angelo, Scalvenzi, Massimiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412060/
https://www.ncbi.nlm.nih.gov/pubmed/37557166
http://dx.doi.org/10.5826/dpc.1303a177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10412060/
https://www.ncbi.nlm.nih.gov/pubmed/37557166
http://dx.doi.org/10.5826/dpc.1303a177

Ejemplares similares